drugset / Trial / NCT00744263

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

NCT00744263

Phase 4 Completed 84496 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

Timeline

Start
2008-09
Primary completion
2013-10
Completion
2013-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Prevnar 13 Vaccine 0.5 ml Intramuscular